Venrock’s Post

More than a dozen states have enacted legislation requiring payers to start covering the expensive biomarker testing used in cancer and other specialty treatments, and more may be on the way. Attorney Bob Hearn discusses why the changing legal landscape gives payers discretion, in a Health Payer Specialist article by Rachel Dalloo. [Excerpt and links.] #Laboratories #LifeSciences #Healthcare

Since my time Pfizer about 10 years ago working with Aaron Deves, Jennifer O'Donnell and George Migias, we knew healthcare capacity could not meet the demand for new #alzheimersdisease treatments. At the time, it was all theoretical due to the lack of new treatments. This excellent piece by Alzforum outlines these system issues now made evident by the launch of the first widely available DMT, #leqembi from Eisai US and Biogen. These companies, organizations, like Davos Alzheimer's Collaborative, are working to address these issues - and get innovative treatment to market. Good to see the focus! https://lnkd.in/eEax_SAV

A huge step forward for digital therapeutics: Medicare is proposing to establish new codes for Digital Mental Health Treatment (DMHT) devices. Up until now, there has not been a clear and standardized way for digital therapeutics to be reimbursed under the traditional healthcare system. The 2025 Medicare Physician Fee Schedule Proposed Rule changes that. Not only will this (if/when finalized) be the first real way for DTx to be reimbursed by Medicare, but we can expect health plans to soon follow. There's still a lot of questions up in the air but this is a industry-changing moment for digital therapeutics. Read more here:

Patient Assistance Programs: Unlocking the Potential of Real-World Data 🧬 In the rapidly advancing field of drug development, Patient Assistance Programs (PAPs) are proving to be invaluable beyond their initial purpose—they’re becoming a critical source of real-world data (RWD). At MedMind, we’re dedicated to harnessing data to improve patient outcomes and advance healthcare innovation. The integration of RWD from PAPs offers an opportunity to enhance clinical trials, refine therapeutic strategies, and ensure that new treatments are truly effective in real-world settings. MedMind is committed to leveraging these insights to support our mission of transforming healthcare through data-driven solutions. PAPs are not just about access—they’re about paving the way for the future of medicine. 🔗 https://lnkd.in/g6DBwgtz #DrugDevelopment #RealWorldData #PatientAssistancePrograms #HealthcareInnovation

The utilization of pay-for-performance agreements to justify steep costs, such as Lenmeldy's $4.25 million price tag, has to raise questions about accessibility and affordability for patients. While these agreements may seem necessary for securing insurer buy-in, the implications for patients and their families extend beyond the negotiating table. For patient advocacy teams in #biopharma, this dynamic presents a challenge. On one hand, they are tasked with advocating for fair pricing and equitable access to groundbreaking therapies like Lenmeldy, aligning with their mission to enhance patient outcomes and quality of life. On the other hand, they must navigate the intricate landscape of drug pricing and reimbursement, striking a delicate balance between sustainability and affordability. It's imperative to recognize that the true impact of drug pricing echos through the lives of patients and their loved ones. Ensuring that innovative therapies remain accessible and affordable is not just a matter of economics it needs to be at the center of the #PharmaceuticalIndustry. #PatientAdvocacy #DrugPricing #HealthcareAccess #Affordability #PatientOutcomes

The increasing use of #biosimilars has quickly put to rest any questions about their safety and efficacy. Since 2015, biosimilars have been used in almost 700 million days of patient therapy. Learn more in AAM's #GRxBiosimsSavingsReport: https://lnkd.in/eBR7yBmJ Biosimilars Council

The healthcare system is ridden with friction and barriers. Fortunately, change is underway — better-designed Patient Support Programs are on the horizon. Read Jay Erickson's article on the promise of this transformative shift: https://hubs.la/Q02w7W030 #PSP #patientsupportprograms #pharma #healthcare

Patient services are undergoing rapid changes based on regulatory requirements and evolving patient and prescriber expectations. Read the full debrief from this year’s Asembia Summit from Senior Director, Patient Access Services Cathy Patten: https://hubs.li/Q02xfrlP0 #PatientsFirst #Asembia24 #Pharma #PatientServices

When we embrace real-world data alongside controlled trials, we can bridge the gap between the ideal world of medical research and the messy reality of patient care. This is the recipe for real-world evidence. Shifting to RWE will lead to faster drug approvals, more personalized treatment plans, and a more holistic understanding of how medications work in the real world rather than in limited scenarios. #RWD #RWE #Healthcare

🌟 Exciting News from Wellthy Therapeutics 🌟 We are thrilled to announce a monumental step forward in our mission to impact 10 million patient lives: Wellthy Therapeutics is now a part of the TruDoc family. This union marks the beginning of a new era in healthcare, where the synergy between TruDoc's Digital Primary Care services and Wellthy Therapeutics' cutting-edge chronic disease management solutions sets new benchmarks in patient-centric care. Together, we are breaking barriers and creating a healthcare ecosystem that is more accessible, personalized, and efficient than ever before. Our combined expertise means patients across the globe will now have 24/7 access to full-stack virtual primary care. This model not only addresses immediate healthcare needs but also empowers individuals in managing chronic conditions, ensuring a healthier tomorrow for millions. 🔍 Why is this a game-changer? 1️⃣ Enhanced Access: Round-the-clock access to quality healthcare, regardless of geographical barriers. 2️⃣ Personalized Care: Tailored health plans that address individual patient needs, leveraging the power of digital therapeutics. 3️⃣ Improved Outcomes: A streamlined healthcare delivery model that optimizes costs and improves outcomes. As we embark on this exciting journey, we invite you to join us in celebrating this milestone. Stay tuned as we unfold more about how we're transforming healthcare delivery, one patient at a time. Together, we're not just setting new benchmarks; we're redefining what it means to put patients first. Link to the article in the comments #insighttoimpact #beyondboundaries #fullstackhealth #TruDocxWellthy #wellthytherapeutics #TruDoc